Intravitreal triamcinolone acetonide for patients with macular oedema due to central retinal vein occlusion in Taiwan.
To evaluate the safety and outcome of intravitreal triamcinolone acetonide as treatment for macular oedema secondary to central retinal vein occlusion (CRVO) in Taiwanese. The prospective clinical interventional study included 43 patients (43 eyes) with macular oedema due to CRVO. The study group consisted of 22 patients who had accepted an intravitreal injection of 4 mg of triamcinolone acetonide. The control group included 21 patients without intravitreal triamcinolone acetonide. Examination included assessment of best-corrected visual acuity, slit-lamp biomicroscopy, measurement of intraocular pressure, ophthalmoscopy, and optical coherence tomography (OCT). The mean follow-up was 283.00+/-70.62 days in the study group and 354.05+/-173.18 days in the control group, respectively. In the study group, visual acuity measurements improved significantly (P=0.007) from 1.00+/-0.45 logMAR preoperatively to a best postoperative visual acuity of 0.67+/-0.65 logMAR. Seventeen eyes (77.3%) gained improvement in visual acuity with 12 eyes (54.5%) showing an increase in visual acuity of at least two Snellen lines. All 22 patients showed significant macular oedema resolution in OCT examination (P<0.001) from 594.36+/-177.78 mum preoperatively to a mean retinal thickness of 317.23+/-196.83 mum postoperatively postintravitreal injection. In the control group, baseline best-corrected visual acuity and best-corrected visual acuity during the follow-up did not vary significantly (P=0.457). Intravitreal triamcinolone acetonide can lead to a significant improvement in visual acuity and a resolution of macular oedema in patients with CRVO.